S&P 500   4,248.72 (+0.91%)
DOW   33,595.05 (+0.86%)
QQQ   329.57 (+1.12%)
AAPL   170.68 (+0.85%)
MSFT   290.35 (+0.41%)
META   182.76 (+2.48%)
GOOGL   121.39 (+1.41%)
AMZN   144.31 (+1.14%)
TSLA   882.12 (-0.11%)
NVDA   186.10 (+2.83%)
NIO   21.70 (+8.23%)
BABA   97.34 (+5.31%)
AMD   102.01 (+2.99%)
MU   63.83 (+3.96%)
T   18.15 (+0.78%)
CGC   3.42 (+3.95%)
GE   78.55 (+1.83%)
F   15.76 (+1.68%)
DIS   121.55 (+8.11%)
AMC   26.01 (+9.89%)
PYPL   101.66 (+2.78%)
PFE   48.54 (-2.82%)
NFLX   250.59 (+2.65%)
S&P 500   4,248.72 (+0.91%)
DOW   33,595.05 (+0.86%)
QQQ   329.57 (+1.12%)
AAPL   170.68 (+0.85%)
MSFT   290.35 (+0.41%)
META   182.76 (+2.48%)
GOOGL   121.39 (+1.41%)
AMZN   144.31 (+1.14%)
TSLA   882.12 (-0.11%)
NVDA   186.10 (+2.83%)
NIO   21.70 (+8.23%)
BABA   97.34 (+5.31%)
AMD   102.01 (+2.99%)
MU   63.83 (+3.96%)
T   18.15 (+0.78%)
CGC   3.42 (+3.95%)
GE   78.55 (+1.83%)
F   15.76 (+1.68%)
DIS   121.55 (+8.11%)
AMC   26.01 (+9.89%)
PYPL   101.66 (+2.78%)
PFE   48.54 (-2.82%)
NFLX   250.59 (+2.65%)
S&P 500   4,248.72 (+0.91%)
DOW   33,595.05 (+0.86%)
QQQ   329.57 (+1.12%)
AAPL   170.68 (+0.85%)
MSFT   290.35 (+0.41%)
META   182.76 (+2.48%)
GOOGL   121.39 (+1.41%)
AMZN   144.31 (+1.14%)
TSLA   882.12 (-0.11%)
NVDA   186.10 (+2.83%)
NIO   21.70 (+8.23%)
BABA   97.34 (+5.31%)
AMD   102.01 (+2.99%)
MU   63.83 (+3.96%)
T   18.15 (+0.78%)
CGC   3.42 (+3.95%)
GE   78.55 (+1.83%)
F   15.76 (+1.68%)
DIS   121.55 (+8.11%)
AMC   26.01 (+9.89%)
PYPL   101.66 (+2.78%)
PFE   48.54 (-2.82%)
NFLX   250.59 (+2.65%)
S&P 500   4,248.72 (+0.91%)
DOW   33,595.05 (+0.86%)
QQQ   329.57 (+1.12%)
AAPL   170.68 (+0.85%)
MSFT   290.35 (+0.41%)
META   182.76 (+2.48%)
GOOGL   121.39 (+1.41%)
AMZN   144.31 (+1.14%)
TSLA   882.12 (-0.11%)
NVDA   186.10 (+2.83%)
NIO   21.70 (+8.23%)
BABA   97.34 (+5.31%)
AMD   102.01 (+2.99%)
MU   63.83 (+3.96%)
T   18.15 (+0.78%)
CGC   3.42 (+3.95%)
GE   78.55 (+1.83%)
F   15.76 (+1.68%)
DIS   121.55 (+8.11%)
AMC   26.01 (+9.89%)
PYPL   101.66 (+2.78%)
PFE   48.54 (-2.82%)
NFLX   250.59 (+2.65%)
NASDAQ:PRPO

Precipio - PRPO Stock Forecast, Price & News

$1.56
+0.04 (+2.63%)
(As of 08/11/2022 09:53 AM ET)
Add
Compare
Today's Range
$1.56
$1.57
50-Day Range
$1.06
$1.63
52-Week Range
$0.91
$4.17
Volume
220 shs
Average Volume
309,932 shs
Market Capitalization
$35.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PRPO stock logo

About Precipio (NASDAQ:PRPO) Stock

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

Precipio Trading Up 2.7 %

PRPO opened at $1.52 on Thursday. The stock has a 50-day moving average price of $1.21 and a 200-day moving average price of $1.23. The company has a quick ratio of 2.47, a current ratio of 2.59 and a debt-to-equity ratio of 0.01. Precipio has a 1 year low of $0.91 and a 1 year high of $4.17.

Precipio (NASDAQ:PRPO - Get Rating) last released its quarterly earnings results on Wednesday, May 11th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter. The firm had revenue of $2.45 million for the quarter. Precipio had a negative net margin of 123.12% and a negative return on equity of 46.63%.

Receive PRPO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precipio and its competitors with MarketBeat's FREE daily newsletter.

PRPO Stock News Headlines

When Will Precipio, Inc. (NASDAQ:PRPO) Breakeven?
Precipio Signs First IV-Cell Customer Agreement
See More Headlines
Receive PRPO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precipio and its competitors with MarketBeat's FREE daily newsletter.

PRPO Company Calendar

Last Earnings
8/23/2018
Today
8/11/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRPO
Employees
54
Year Founded
N/A

Profitability

Net Income
$-8,530,000.00
Net Margins
-123.12%
Pretax Margin
-122.99%

Debt

Sales & Book Value

Annual Sales
$8.85 million
Book Value
$1.08 per share

Miscellaneous

Free Float
20,779,000
Market Cap
$35.43 million
Optionable
Not Optionable
Beta
2.15














PRPO Stock - Frequently Asked Questions

How have PRPO shares performed in 2022?

Precipio's stock was trading at $1.58 at the start of the year. Since then, PRPO shares have decreased by 3.8% and is now trading at $1.52.
View the best growth stocks for 2022 here
.

Are investors shorting Precipio?

Precipio saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 90,200 shares, a decline of 29.8% from the July 15th total of 128,500 shares. Based on an average trading volume of 278,800 shares, the short-interest ratio is presently 0.3 days.
View Precipio's Short Interest
.

When is Precipio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our PRPO earnings forecast
.

How were Precipio's earnings last quarter?

Precipio, Inc. (NASDAQ:PRPO) issued its earnings results on Thursday, August, 23rd. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.93 by $2.08. The biotechnology company had revenue of $0.82 million for the quarter. Precipio had a negative net margin of 123.12% and a negative trailing twelve-month return on equity of 46.63%.

When did Precipio's stock split?

Precipio's stock reverse split on Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Precipio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Biocept (BIOC), Heat Biologics (HTBX), Portola Pharmaceuticals (PTLA), iBio (IBIO), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), VBI Vaccines (VBIV), Co-Diagnostics (CODX), Inpixon (INPX) and Jaguar Health (JAGX).

What is Precipio's stock symbol?

Precipio trades on the NASDAQ under the ticker symbol "PRPO."

Who are Precipio's major shareholders?

Precipio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Great Valley Advisor Group Inc. (0.15%). Insiders that own company stock include Ahmed Zaki Sabet, David Seth Cohen and Ilan Danieli.
View institutional ownership trends
.

How do I buy shares of Precipio?

Shares of PRPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Precipio's stock price today?

One share of PRPO stock can currently be purchased for approximately $1.52.

How much money does Precipio make?

Precipio (NASDAQ:PRPO) has a market capitalization of $34.52 million and generates $8.85 million in revenue each year. The biotechnology company earns $-8,530,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.

How can I contact Precipio?

Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The official website for the company is www.precipiodx.com. The biotechnology company can be reached via phone at (203) 787-7888, via email at investors@precipiodx.com, or via fax at 402-452-5401.

This page (NASDAQ:PRPO) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.